An Evaluation of the Pharmacokinetic Profile and Safety of a Single Dose of Daptomycin in Pediatric Subjects Aged 3 Months to Twenty-Four Months Who Are Concurrently Receiving Standard Antibiotic Therapy for Proven or Suspected Bacterial Infection Including Peri-Operative Prophylactic Use of Antibiotics.

Trial Profile

An Evaluation of the Pharmacokinetic Profile and Safety of a Single Dose of Daptomycin in Pediatric Subjects Aged 3 Months to Twenty-Four Months Who Are Concurrently Receiving Standard Antibiotic Therapy for Proven or Suspected Bacterial Infection Including Peri-Operative Prophylactic Use of Antibiotics.

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Nov 2015

At a glance

  • Drugs Daptomycin (Primary)
  • Indications Gram-positive infections
  • Focus Pharmacokinetics
  • Sponsors Cubist Pharmaceuticals
  • Most Recent Events

    • 23 May 2012 Actual patient number 23 added as reported by ClinicalTrials.gov.
    • 23 May 2012 Actual end date 1 Mar 2012 added as reported by ClinicalTrials.gov.
    • 23 May 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top